AstraZeneca PLC
Sweden · GB0009895292 · reports in USD · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +8.6% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 21% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 43% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
$58.7B
revenue
23%
operating margin
$10.2B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $44.4B | $45.8B | $54.1B | $58.7B |
| Operating profit | $3.8B | $8.2B | $10.0B | $13.7B |
| Net profit to shareholders | $3.3B | $6.0B | $7.0B | $10.2B |
| Earnings per share | $2.12 | $3.84 | $4.54 | $6.60 |
| Cash from operations | $9.8B | $10.3B | $11.9B | $14.6B |
| Capital spending | $1.1B | $1.4B | $1.9B | $2.8B |
| Cash | $6.2B | n/a | $5.5B | $5.7B |
| Total assets | $96.5B | n/a | $104.0B | $114.1B |
| Equity | $37.1B | $39.2B | $40.9B | $48.7B |
What they do
In the company's own words, from the annual report.
AstraZeneca’s pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.